ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

This study has been completed.

Sponsors and Collaborators: New York University School of Medicine
The Cleveland Clinic
Centocor, Inc.
Eli Lilly and Company
Information provided by: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00245648
  Purpose

This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.


Condition Intervention Phase
Myocardial Infarcton
Drug: fibrinolytic therapy or combination reduced fibrinolytic therapy
Phase III

ChemIDplus related topics:   Alteplase    Tissue-type plasminogen activator    Streptokinase   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial

Further study details as provided by New York University School of Medicine:

Detailed Description:

The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V trial examined a large, contemporary cohort of women and men with ST elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was to evaluate sex differences in presentation, management and outcome in GUSTO V.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Criteria

Inclusion Criteria:

  • inclusion into GUSTO V

Exclusion Criteria:

  • lack of availability of data (database study)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00245648

Locations
United States, New York
NYU School of Medicine    
      New York, New York, United States, 10016

Sponsors and Collaborators
New York University School of Medicine
The Cleveland Clinic
Centocor, Inc.
Eli Lilly and Company

Investigators
Principal Investigator:     Harmony Reynolds     NYU School of Medicine    
  More Information

Publications:

Publications indexed to this study:

Study ID Numbers:   GUSTOVsex
First Received:   October 27, 2005
Last Updated:   October 27, 2005
ClinicalTrials.gov Identifier:   NCT00245648
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Death
Tissue Plasminogen Activator
Streptokinase
Hemorrhage
Plasminogen

Additional relevant MeSH terms:
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Hematologic Agents
Fibrinolytic Agents
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2008




Links to all studies - primarily for crawlers